塞拉万斯生物制药 TBPH
$0.00 +$0.00 (0.00%)
休市 · Oct 24, 12:40 am ET
开盘$0.00
昨收$0.00
当日区间$0.00 – $0.00
成交量0.00
市值$884.18M
市盈率（TTM）16.4
股息率–
财报
财报日平均波动±6.6%近16次财报
收涨次数10 / 1663% 的概率
最佳反应+22.7%
最差反应-18.4%
每次财报后次日股价变动
| 季度 | 财报日期 | 时段 | 隐含波动 | 实际波动 | 较隐含波动 |
|---|---|---|---|---|---|
| 2025/Q3 | 10 Nov 2025 | After Market | ±22.0% | +22.68% | 超出定价预期 |
| 2025/Q2 | 12 Aug 2025 | After Market | ±14.1% | +4.19% | 符合区间 |
| 2025/Q1 | 8 May 2025 | After Market | ±9.5% | -9.29% | 符合区间 |
| 2024/Q4 | 26 Feb 2025 | After Market | ±22.1% | +2.09% | 符合区间 |
| 2024/Q3 | 12 Nov 2024 | After Market | ±13.8% | +8.64% | 符合区间 |
| 2024/Q2 | 5 Aug 2024 | After Market | ±12.3% | -18.35% | 超出定价预期 |
| 2024/Q1 | 13 May 2024 | After Market | ±7.8% | -1.98% | 符合区间 |
| 2023/Q4 | 26 Feb 2024 | After Market | ±17.6% | +4.98% | 符合区间 |
| 2023/Q3 | 7 Nov 2023 | After Market | ±6.7% | +5.34% | 符合区间 |
| 2023/Q2 | 7 Aug 2023 | After Market | ±9.7% | -0.92% | 符合区间 |
| 2023/Q1 | 8 May 2023 | After Market | ±13.7% | +0.44% | 符合区间 |
| 2022/Q4 | 27 Feb 2023 | After Market | ±19.6% | +2.27% | 符合区间 |
| 2022/Q3 | 7 Nov 2022 | After Market | ±6.5% | +3.08% | 符合区间 |
| 2022/Q2 | 4 Aug 2022 | After Market | ±16.6% | -7.81% | 符合区间 |
| 2022/Q1 | 5 May 2022 | None | ±15.4% | -4.21% | 符合区间 |
| 2021/Q4 | 23 Feb 2022 | None | ±29.6% | +9.00% | 符合区间 |
"隐含波动"指财报发布前期权市场定价的预期波幅。"波动"指财报发布后首个交易日的股价变化。
基本面
最新报告季度：Q2, ended Jun 2026
营收$20.73M-20.9% YoY
营业利润$1.84M+167.6% YoY
净利润-$5.90M-110.8% YoY
摊薄每股收益-$0.11-110.2% YoY
自由现金流-$6.97M-103.3% YoY
经营现金流-$6.97M
营收，近8个季度
净利润，近8个季度
盈利能力与资产负债表
营业利润率9.2%
净利率51.6%
净资产收益率20.9%
资产收益率12.0%
投入资本回报率14.0%
流动比率13.54
负债/资产比率38.3%
现金及投资$387.66M
总负债$27.77M
净现金（净负债）$359.88M
自由现金流/营收51.5%
暂无评论——快来第一个聊聊 TBPH。
登录后参与讨论。